7 Needs context
In a meta-analysis of 23 clinical studies involving over 6,000 participants, vitamin C supplementation of at least 2 grams daily reduced cold duration in adults by 21% and in children by 26%, compared to 6% in adults and 17% in children with 1 gram daily.
"A meta-analysis of 23 clinical studies involving more than 6,000 participants sifted through these different factors and found that supplementation of at least 2 grams per day of vitamin C during a cold had a greater benefit compared to a dose of 1 gram per day. A sub-analysis of five of those studies showed that a higher dose of vitamin C supplementation was more effective against colds in children under 16 compared to adults. In adults, cold duration decreased 21% with 2 grams daily and decreased 6% with just 1 gram daily. But in children, cold duration decreased 26% with 2 grams daily and 17% with 1 gram daily." (said at 0:23:33)
The cited figures originate from a 1999 meta-analysis by Harri Hemilä reviewing 23 placebo-controlled trials of vitamin C supplementation (≥1 g/day) totaling over 6,000 participants. That paper found a dose-response relationship and greater benefits in children than adults, including a 6% median reduction in adult cold duration at 1 g/day and a 26% median reduction in children at 2 g/day. However, the speaker mischaracterizes the timing: these 23 trials evaluated regular, continuous daily supplementation (prophylaxis), not supplementation initiated 'during a cold' (therapeutic use). The Cochrane systematic review (PMID 23440782) confirms that regular supplementation reduces cold duration (by ~8% in adults and ~14% in children), but trials of therapeutic supplementation started only at symptom onset have failed to show consistent benefits.
- partial: Vitamin C supplementation and common cold symptoms: factors affecting the magnitude of the… (Medical hypotheses 1999) · cited 64x in the literature
"In this paper, 23 studies with regular vitamin C supplementation (> or = 1 g/day) were analyzed to find out factors that may explain some part of the variation in the results. It was found that on average, vitamin C produces greater benefit for children than for adults. The dose may also affect the magnitude of the benefit, there being on average greater benefit from > or = 2 g/day compared to 1 g/day of the vitamin. In five studies with adults administered 1 g/day of vitamin C, the median decrease in cold duration was only 6%, whereas in two studies with children administered 2 g/day the median decrease was four times higher, 26%. The trials analyzed in this work used regular vitamin C supplementation, but it is conceivable that therapeutic supplementation starting early at the onset of the cold episode could produce comparable benefits." (abstract, results and conclusions, passage verified)
pubmedfull study (doi) - context: Vitamin C for preventing and treating the common cold. (The Cochrane database of systematic reviews 2013) · cited 818x in the literature
"Thirty-one comparisons examined the effect of regular vitamin C on common cold duration (9745 episodes). In adults the duration of colds was reduced by 8% (3% to 12%) and in children by 14% (7% to 21%). In children, 1 to 2 g/day vitamin C shortened colds by 18%. The severity of colds was also reduced by regular vitamin C administration.Seven comparisons examined the effect of therapeutic vitamin C (3249 episodes). No consistent effect of vitamin C was seen on the duration or severity of colds in the therapeutic trials." (abstract, results, passage verified)
pubmedfull study (doi)
A meta-analysis of nine trials found that combining prophylactic vitamin C with therapeutic doses reduced cold symptom duration by about half a day, whereas therapeutic dosing initiated only at symptom onset had no effect.
"Another meta-analysis of nine studies compared the administration of vitamin C as a prophylactic measure, in other words, before you get sick, versus a therapeutic measure. One group of participants took prophylactic doses of 1 to 3 grams every day over the course of several months, and then they took a therapeutic dose of up to 6 grams a day on the onset of cold symptoms. The [other] group only took the therapeutic dose. The prophylactic-therapeutic combo reduced both the symptoms and the duration of a cold episode by about a half a day, but the therapeutic doses given only at the onset of symptoms had no effect." (said at 0:24:04)
The host accurately describes the reported findings of a 2018 meta-analysis of nine trials, which found that administering extra therapeutic doses of vitamin C at cold onset on top of regular daily prophylactic supplementation reduced cold duration by 0.56 days (about half a day). Additionally, Cochrane systematic reviews confirm that therapeutic vitamin C initiated only after symptom onset (without prior regular supplementation) shows no consistent effect on cold duration or severity. However, the 2018 meta-analysis of nine trials was subsequently retracted by the publishing journal, rendering its conclusions unreliable.
Respiratory disease is the fifth leading cause of death in the United States.
"As it turns out, vitamin C might be protective against many respiratory diseases, the fifth leading cause of death among people living in the United States." (said at 0:28:47)
Respiratory disease—specifically chronic lower respiratory disease (CLRD)—is consistently recognized by the CDC as one of the top five leading causes of death in the United States, alongside heart disease, cancer, unintentional injuries, and stroke. However, standard CDC mortality data historically rank CLRD as the 3rd or 4th leading cause of death rather than the 5th (with stroke or unintentional injuries often occupying the 5th spot depending on the year).
- context: Potentially preventable deaths from the five leading causes of death--United States, 2008-… (MMWR. Morbidity and mortality weekly report 2014) · cited 186x in the literature
"In 2010, the top five causes of death in the United States were 1) diseases of the heart, 2) cancer, 3) chronic lower respiratory diseases, 4) cerebrovascular diseases (stroke), and 5) unintentional injuries." (abstract, results, passage verified)
pubmed - context: Deaths: Leading Causes for 2015. (National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System 2017) · cited 67x in the literature
"In 2015, the 10 leading causes of death were, in rank order: Diseases of heart; Malignant neoplasms; Chronic lower respiratory diseases; Accidents (unintentional injuries); Cerebrovascular diseases; Alzheimer's disease; Diabetes mellitus; Influenza and pneumonia; Nephritis, nephrotic syndrome and nephrosis; and Intentional self-harm (suicide)." (abstract, results, passage verified)
pubmed
A study of 47 sepsis patients treated with IV vitamin C (6 g/day), hydrocortisone, and thiamine reported an 8% mortality rate compared to roughly 40% in historical controls receiving standard of care.
"A separate study treated 47 sepsis patients with 6 grams of intravenous vitamin C four times per day for four days along with hydrocortisone, a type of steroid medication, and thiamine, a type of B vitamin. A control group of 47 other sepsis patients received the standard of care. Roughly 40% of the patients in the control group died, but roughly 8% of the patients in the vitamin C treated group died." (said at 0:54:50)
The host accurately summarizes the findings of a widely publicized 2017 retrospective before-after study (Marik et al.), which evaluated 47 severe sepsis and septic shock patients treated with intravenous vitamin C (1.5 g every 6 hours, totaling 6 g/day), hydrocortisone, and thiamine compared to 47 historical control patients. In that specific study, hospital mortality was 8.5% (4/47) in the treatment group compared to 40.4% (19/47) in the control group. However, because this was a non-randomized, single-center observational study, its findings represent very low-certainty evidence. Subsequent rigorous randomized controlled trials and meta-analyses have consistently failed to replicate a mortality benefit for this combination therapy in sepsis.
- supports: Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shoc… (Chest 2017) · cited 892x in the literature
"There were 47 patients in both treatment and control groups, with no significant differences in baseline characteristics between the two groups. The hospital mortality was 8.5% (4 of 47) in the treatment group compared with 40.4% (19 of 47) in the control group (P < .001)." (abstract, results, passage verified)
pubmedfull study (doi) - context: Thiamine, Ascorbic Acid, and Hydrocortisone As a Metabolic Resuscitation Cocktail in Sepsi… (Critical care medicine 2021) · cited 56x in the literature
"There was no evidence of a difference regarding the ICU mortality and the renal composite outcome (acute kidney injury KDIGO 3 or need for renal replacement therapy, seven randomized controlled trials)." (abstract, results, passage verified)
pubmedfull study (doi)
A randomized study of nearly 400 healthy adults found that daily supplementation with 1 gram of vitamin C and 800 IU of vitamin E for two months decreased C-reactive protein by nearly 17% in participants with elevated baseline CRP.
"A randomized study of nearly 400 healthy adults who took 1 gram of vitamin C, 800 IUs of vitamin E, or a placebo every day for two months looked at whether antioxidants could lower C-reactive protein, an inflammatory biomarker associated with cardiovascular disease risk. The vitamin C and E decreased C-reactive protein nearly 17% compared to pretreatment measurements, but only in people who had elevated baseline levels of C-reactive protein." (said at 1:01:01)
In a randomized controlled trial of 396 healthy nonsmoking adults (Block et al., 2009), participants received 1000 mg/day of vitamin C, 800 IU/day of vitamin E, or a placebo for 2 months. In the subgroup of participants with elevated baseline CRP (≥1.0 mg/L), vitamin C supplementation led to a 16.7% median reduction from baseline (a 25.3% reduction compared to placebo). However, the study found no significant reduction in CRP in the vitamin E group, so the effect was specific to vitamin C rather than both antioxidants.
- partial: Vitamin C treatment reduces elevated C-reactive protein. (Free radical biology & medicine 2009) · cited 113x in the literature
"Healthy nonsmokers (N=396) were randomized to three groups, 1000 mg/day vitamin C, 800 IU/day vitamin E, or placebo, for 2 months. Median baseline CRP was low, 0.85 mg/L. No treatment effect was seen when all participants were included. However, a significant interaction was found, indicating that treatment effect depends on baseline CRP concentration. Among participants with CRP indicative of elevated cardiovascular risk (> or =1.0 mg/L), vitamin C reduced the median CRP by 25.3% vs placebo (p=0.02) (median reduction in the vitamin C group, 0.25 mg/L, 16.7%). These effects are similar to those of statins. The vitamin E effect was not significant. In summary, treatment with vitamin C but not vitamin E significantly reduced CRP among individuals with CRP > or =1.0 mg/L." (abstract, results, passage verified)
pubmedfull study (doi)
Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at risk of hemolysis when given intravenous vitamin C at doses of 40 grams or higher.
"In addition, people who have a deficiency in the enzyme glucose-6-phosphate dehydrogenase are at risk of hemolysis—the rupturing of red blood cells—when given high doses of intravenous vitamin C. It's worth noting that the intravenous doses used in these studies were 40 grams or higher." (said at 1:09:45)
The core assertion is accurate: individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency face a recognized risk of acute hemolytic anemia when administered high-dose intravenous vitamin C, making routine G6PD pre-screening standard clinical practice before high-dose therapy. However, the claim requires context regarding dose: while many high-dose protocol studies use 40 grams or more, hemolysis in G6PD-deficient patients is not restricted to doses ≥40 grams; documented cases of severe hemolysis have occurred at lower intravenous doses, such as 30 grams.
- supports: Harm of IV High-Dose Vitamin C Therapy in Adult Patients: A Scoping Review. (Critical care medicine 2020) · cited 81x in the literature
"reports of oxalate nephropathy, hypernatremia, glucometer error, and hemolysis in glucose-6-phosphate dehydrogenase deficiency patients warrant specific monitoring." (abstract, conclusions, passage verified)
pubmedfull study (doi) - context: High dose vitamin C induced methemoglobinemia and hemolytic anemia in glucose-6-phosphate … (The American journal of emergency medicine 2020) · cited 25x in the literature
"A 75-year-old woman presented with acute onset of jaundice, dark urine and shortness of breath after receiving 30 g of vitamin C infusion as an unconventional therapy for her hemifacial spasm. Diagnosis of methemoglobinemia and hemolytic anemia was made clinically and confirmed on laboratory tests." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Vitamin C-induced Hemolysis: Meta-summary and Review of Literature. (Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 2022) · cited 7x in the literature
"Physicians should be aware of potential complications like severe hemolysis and AKI, especially when using high doses and in G6PD deficiency." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: Clinical benefits and risks of high-dose intravenous vitamin C: a systematic review. (Journal of medicine and life 2026)
"Some of the major risks include oxalate nephropathy and hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency, especially with very large or repeated doses, suggesting pre-screening to avoid these risks." (abstract, results, passage verified)
pubmedfull study (doi)
Clinical studies of high-dose intravenous vitamin C in cancer patients have not reported impairments in kidney function.
"Studies of high-dose intravenous vitamin C in cancer patients have not reported any impairments in kidney function." (said at 1:13:30)
A systematic review of 23 Phase I/II clinical trials evaluating intravenous ascorbate in 385 cancer patients found that high-dose intravenous vitamin C was generally safe and well tolerated, with no significant renal impairments reported in these trial cohorts. However, clinical trials routinely screen and exclude patients with pre-existing renal impairment or history of kidney stones due to the metabolic conversion of ascorbate to oxalate, which carries a known risk of oxalate nephropathy in susceptible individuals.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.